Author/Editor		Šabovič, Mišo
Title		Pharmacological threatment of coronary atherosclerosis
Type		članek
Source		In: Pajer Z, Štiblar-Martinčič D, editors. International symposium on cardiovascular diseases. Proceedings of the 29th memorial meeting devoted to prof. dr. Janez Plečnik; 1998 Dec 3-5; Ljubljana. Ljubljana: Medical faculty, Institute of histology and embryology,
Publication year		1998
Volume		str. 99-106
Language		eng
Abstract		Coronary atherosclerosis is the leading cause of death in industrialised countries. The endemic nature of this disease has made it the focus of intense clinical research. In recent years, it has been established in humans that progression of atherosclerosis can be slowed, and in some cases, reversed. Most importantantly, the delay in the progression of atherosclerosis has been clearly associated with a decrease in cardiovascular mortality and morbidity. Severaldrugs with potential anti-atherosclerotic effects (lipid-lowering drugs, angiotensin converting enzyme inhibitors, antixodidants, calcium channel blocking agetns, estrogens, antibiotics, anti-infalmmatory agents,homocystein-lowering vitamins, beta adrenergic receptors blocking agents..) are under extensive laboratory and clinical investigation. So far, there is an overwhelming body of evidence showing the efficacy of aggresive lipid-lowering treatment, in particular with HMG CoA reductase inhibitors. This article reviews current data in the area of pharmacological treatment of coronary atherosclerosis.
Descriptors		CORONARY ARTERIOSCLEROSIS ANTILIPEMIC AGENTS ANGIOTENSIN-CONVERTING ENZYME INHIBITORS ANTIOXIDANTS CALCIUM CHANNEL BLOCKERS ESTROGEN REPLACEMENT THERAPY ANTIBIOTICS ASPIRIN